Other News

Vizient, Inc. Announces Moving Analytics as the 2018 Innovation Challenge Winner

IRVING, Texas–(BUSINESS WIRE)–Vizient, Inc. today announced Moving Analytics as the winner of its 2018 Innovation Challenge, an interactive competition between four early-stage growth health care companies. The competition was held on Wednesday, Oct. 3, during the opening session of the Vizient Clinical Connections Summit in Las Vegas. The Innovation Challenge is an interactive pitch […]

Eidos Therapeutics to Present Phase 2 Data for AG10 in TTR Amyloidosis Cardiomyopathy at the AHA 2018 Scientific Sessions in a Late-Breaking Featured Science Oral Presentation

SAN FRANCISCO, Oct. 05, 2018 (GLOBE NEWSWIRE) — Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today announced that results of its Phase 2 clinical trial studying AG10 in subjects with symptomatic transthyretin (TTR) amyloidosis cardiomyopathy (ATTR-CM) will be announced in a late-breaking featured science oral presentation at this year’s American Heart Association […]

Teleflex Acquires Essential Medical

WAYNE, Pa.–(BUSINESS WIRE)–Teleflex Incorporated (NYSE: TFX) today announced that it has acquired Essential Medical, Inc. Based in Exton, PA, Essential Medical is a privately-held medical device company that has developed and commercialized the CE Marked MANTA™ Vascular Closure Device specifically designed for closure of large bore arteriotomies following procedures utilizing […]

Adagio Medical Completes Chronic Pre-Clinical Atrial Fibrillation Study Using Ultra-Low Temperature Cryoablation Technology

LAGUNA HILLS, Calif., Oct. 4, 2018 /PRNewswire/ — Adagio Medical, Inc., the developer of the iCLAS™ technology, the company’s ultra-low temperature intelligent continuous lesion ablation system for the treatment of cardiac arrhythmias, announces the successful completion of its chronic atrial fibrillation animal study, performed in collaboration with the LIRYC Research Institute of Bordeaux, […]

EPIX Therapeutics Announces Completion of DIAMOND-AF Paroxysmal Study and First Enrollment in DIAMOND-AF II Persistent Study

SANTA CLARA, Calif., Oct. 4, 2018 /PRNewswire/ — EPIX Therapeutics, Inc., a medical device company that designs and manufactures a catheter-based system for the treatment of patients with atrial fibrillation (AFIB), today announced achievement of the enrollment goal of the DIAMOND-AF study, a global FDA-approved IDE pivotal study to evaluate the DiamondTemp Ablation […]

Acasti Pharma Announces Proposed Underwritten Public Offering of Common Shares

MONTRÉAL, Oct. 03, 2018 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, announced today that it intends to offer and sell its common […]

LuxCath Appoints Terry Ransbury as Chief Technology Officer

BOSTON–(BUSINESS WIRE)–LuxCath, LLC, a medical device company developing a novel cardiac catheter ablation technology, today announced that Terry Ransbury has been appointed its Chief Technology Officer. Mr. Ransbury is a seasoned industry veteran who brings over 30 years of experience in research and development, specializing in electrophysiology and cardiac rhythm […]

AtriCure Announces Proposed Public Offering of Common Stock

MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced it has commenced an underwritten public offering of 2.5 million shares of its common stock pursuant to its existing shelf registration statement. In connection with this offering, […]

Endologix Announces Third Quarter Preliminary Revenue Results and Raises Low End of 2018 Revenue Guidance Range

IRVINE, Calif.–(BUSINESS WIRE)–Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that its preliminary unaudited revenue for the third quarter ended September 30, 2018 is expected to be in the range of $34.3 million to $34.7 million. Also, based on current business trends, […]